← Back to Clinical Trials
Recruiting NCT06547684

NCT06547684 Extracorporeal Shock Wave Therapy on Spastic Equinus Foot in Stroke Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06547684
Status Recruiting
Phase
Sponsor Teresa Mateu Campos
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2020-08-28
Primary Completion 2024-09-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
fESWT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2020-08-28 with a primary completion date of 2024-09-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to evaluate long term effects of focused extracorporeal shock wave therapy (fESWT) on triceps surae spasticity in stroke patients according to the number of sessions applied. Hypothesis: 3 sessions of fESWT on equinus foot in stroke patients improve spasticity and functionality for longer term than 1 session of fESWT.

Eligibility Criteria

Inclusion Criteria: * Age greater than 18 years old * Time from stroke (ischemic o hemorrhagic) onset of at least 6 months * Spastic equinus foot: triceps surae tone grade at least 1+ on the MAS score * Ability to walk alone with or without aids Exclusion Criteria: * Fixed ankle joint contracture * Severe medical problems * Treatment of the affected leg with botulinum toxin in the las 6 months * Cognitive impairment

Contact & Investigator

Central Contact

Teresa Mª Mateu Campos

✉ teremateuc@gmail.com

📞 +34666803771

Principal Investigator

Teresa Mª Mateu Campos

PRINCIPAL INVESTIGATOR

Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Frequently Asked Questions

Who can join the NCT06547684 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06547684 currently recruiting?

Yes, NCT06547684 is actively recruiting participants. Contact the research team at teremateuc@gmail.com for enrollment information.

Where is the NCT06547684 trial being conducted?

This trial is being conducted at Vila-real, Spain.

Who is sponsoring the NCT06547684 clinical trial?

NCT06547684 is sponsored by Teresa Mateu Campos. The principal investigator is Teresa Mª Mateu Campos at Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology